Novartis AG ADR (NVS)

89.49
-0.35(-0.39%)
After Hours
89.95
+0.46(+0.51%)
- Real-time Data
  • Volume:
    1,701,837
  • Day's Range:
    89.27 - 89.99
  • 52 wk Range:
    74.09 - 94.26

NVS Overview

Prev. Close
89.84
Day's Range
89.27-89.99
Revenue
38.74B
Open
89.34
52 wk Range
74.09-94.26
EPS
9.88
Volume
1,701,837
Market Cap
193.14B
Dividend (Yield)
2.1614
(2.34%)
Average Vol. (3m)
1,998,750
P/E Ratio
9.09
Beta
0.488
1-Year Change
5.11%
Shares Outstanding
2,150,980,441
Next Earnings Date
Apr 25, 2023
What is your sentiment on Novartis ADR?
or
Market is currently closed. Voting is open during market hours.

Novartis AG ADR Analysis

Novartis AG ADR Company Profile

Novartis AG ADR Company Profile

Employees
108000

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellSellStrong Buy
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Buy
SummaryStrong SellStrong SellStrong SellStrong SellStrong Buy
  • NVS reported solid results for Q1 that included a 10% jump in sales for its top-selling Cosentyx psoriatic arthritis drug. With a diverse portfolio of pharmaceuticals and strong momentum in a down market, NVS is worth a look for many reasons
    1
    • Thanks in part to strong performance, this is one of a few stocks that has posted positive gains in 2022 despite headwinds elsewhere in the market.
      0
      • https://seekingalpha.com/pr/18243773-sellas-life-sciences-reports-full-year-2020-financial-results-and-provides-business-update
        1
        • buy
          0
          • A
            0
            • just to know. I'm lost.this is the company that bought the medicines company?
              0
              • before investing in @novartis, read #teampia (twitter).
                0
                • sell 89 expecting 80 timeframe 5 days
                  1
                  • Long ENDOCYTE... I work in the field
                    0
                    • $NVS: Novartis AG Looking at All Options Including IPO for Alcon Unit.. This is HUGE catalyst for $NVS share holders!!!!!
                      0